Home NDC 0310-6925 QTERNMET
Product NDC 0310-6925
11-digit product format 003106925
Labeler code 0310
Product ID 0310-6925_19500f2f-6cc0-4c18-ad84-e33206608c10
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name dapagliflozin saxagliptin and metformin hydrochloride
Dosage form TABLET, FILM COATED
Route ORAL
Labeler AstraZeneca Pharmaceuticals LP
Application NDA210874
Marketing category NDA
Marketing start 2020-06-01
Marketing end 0000-00-00
Substance DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE; METFORMIN HYDROCHLORIDE
Active strength 3 mg/1; mg/1; mg/1
Pharmacologic classes Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA],Dipeptidyl Peptidase 4 Inhibitor [EPC],Dipeptidyl Peptidase 4 Inhibitors [MoA],Biguanide [EPC],Biguanides [CS]
NDC exclude flag No
Listing certified through 2021-12-31
Current FDA listing Historical FDA.report record
Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 24 matching rows.
View current auxiliary records. · View the auxiliary file history.
Captured / source date, Dataset, Scope table Captured / source date Dataset Scope Package NDC Snapshot Source SHA-256 2025-12-14 17:58 UTC · source 2025-12-05 excluded product product d630ba8d3edf…732f749b63fb…2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 0310-6925-60 d630ba8d3edf…732f749b63fb…2025-08-27 00:01 UTC · source 2025-08-26 excluded product product f5e01cc5f278…a2eaf40c39c3…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 0310-6925-60 f5e01cc5f278…a2eaf40c39c3…2025-04-01 02:39 UTC · source 2025-03-31 excluded product product 2ef7874e63bc…57b86245f4fa…2025-04-01 02:39 UTC · source 2025-03-31 excluded package package 0310-6925-60 2ef7874e63bc…57b86245f4fa…2025-03-28 20:22 UTC · source 2025-03-28 excluded product product a1b67e2a42f9…c4cf2c586c0d…2025-03-28 20:22 UTC · source 2025-03-28 excluded package package 0310-6925-60 a1b67e2a42f9…c4cf2c586c0d…2025-03-22 03:12 UTC · source 2025-03-21 excluded product product cfe11265f3b6…090c488252e2…2025-03-22 03:12 UTC · source 2025-03-21 excluded package package 0310-6925-60 cfe11265f3b6…090c488252e2…2025-03-10 12:48 UTC · source 2025-03-10 excluded product product cdf11ea48f46…ba0047e9e063…2025-03-10 12:48 UTC · source 2025-03-10 excluded package package 0310-6925-60 cdf11ea48f46…ba0047e9e063…2025-02-02 03:52 UTC · source 2025-01-31 excluded product product 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded package package 0310-6925-60 302b2466d912…e7b80fea0513…2025-01-20 13:05 UTC · source 2025-01-20 excluded product product ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded package package 0310-6925-60 ed331223b511…672a5bd82f5f…2025-01-11 03:41 UTC · source 2025-01-10 excluded product product 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded package package 0310-6925-60 0efc9e666f02…f202fb6c5f17…2024-11-09 02:27 UTC · source 2024-11-08 excluded product product ad56d346431e…cc804d4bbf1e…2024-11-09 02:27 UTC · source 2024-11-08 excluded package package 0310-6925-60 ad56d346431e…cc804d4bbf1e…2024-10-04 04:10 UTC · source 2024-10-03 excluded product product 367a005e9d99…383a685ebd0f…2024-10-04 04:10 UTC · source 2024-10-03 excluded package package 0310-6925-60 367a005e9d99…383a685ebd0f…2024-07-10 04:00 UTC · source 2024-07-09 excluded product product 557ba5c1ecfa…9c80585c8c6e…2024-07-10 04:00 UTC · source 2024-07-09 excluded package package 0310-6925-60 557ba5c1ecfa…9c80585c8c6e…
Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 4 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N210874-001 QTERNMET XR DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE 2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 N210874-002 QTERNMET XR DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE 5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 N210874-003 QTERNMET XR DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE 5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 N210874-004 QTERNMET XR DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE 10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02
Orange Book patents# Current patent rows page 1 of 1 · 40 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N210874-001 6515117 2025-10-04 U-493 Drug substance, Drug product 2019-05-24 N210874-001 6515117*PED 2026-04-04 Pediatric extension N210874-001 8501698 2027-06-20 U-493 Drug product 2019-05-24 N210874-001 8501698*PED 2027-12-20 Pediatric extension N210874-001 8716251 2028-03-21 Drug product 2019-05-24 N210874-001 8716251*PED 2028-09-21 Pediatric extension N210874-001 7919598 2029-12-16 Drug substance 2019-05-24 N210874-001 7919598*PED 2030-06-16 Pediatric extension N210874-001 9616028 2030-11-12 Drug product 2019-05-24 N210874-001 9616028*PED 2031-05-12 Pediatric extension N210874-002 6515117 2025-10-04 U-493 Drug substance, Drug product 2019-05-24 N210874-002 6515117*PED 2026-04-04 Pediatric extension N210874-002 8501698 2027-06-20 U-493 Drug product 2019-05-24 N210874-002 8501698*PED 2027-12-20 Pediatric extension N210874-002 8716251 2028-03-21 Drug product 2019-05-24 N210874-002 8716251*PED 2028-09-21 Pediatric extension N210874-002 7919598 2029-12-16 Drug substance 2019-05-24 N210874-002 7919598*PED 2030-06-16 Pediatric extension N210874-002 9616028 2030-11-12 Drug product 2019-05-24 N210874-002 9616028*PED 2031-05-12 Pediatric extension N210874-003 6515117 2025-10-04 U-493 Drug substance, Drug product 2019-05-24 N210874-003 6515117*PED 2026-04-04 Pediatric extension N210874-003 8501698 2027-06-20 U-493 Drug product 2019-05-24 N210874-003 8501698*PED 2027-12-20 Pediatric extension N210874-003 8716251 2028-03-21 Drug product 2019-05-24 N210874-003 8716251*PED 2028-09-21 Pediatric extension N210874-003 7919598 2029-12-16 Drug substance 2019-05-24 N210874-003 7919598*PED 2030-06-16 Pediatric extension N210874-003 9616028 2030-11-12 Drug product 2019-05-24 N210874-003 9616028*PED 2031-05-12 Pediatric extension N210874-004 6515117 2025-10-04 U-493 Drug substance, Drug product 2019-05-24 N210874-004 6515117*PED 2026-04-04 Pediatric extension N210874-004 8501698 2027-06-20 U-493 Drug product 2019-05-24 N210874-004 8501698*PED 2027-12-20 Pediatric extension N210874-004 8716251 2028-03-21 Drug product 2019-05-24 N210874-004 8716251*PED 2028-09-21 Pediatric extension N210874-004 7919598 2029-12-16 Drug substance 2019-05-24 N210874-004 7919598*PED 2030-06-16 Pediatric extension N210874-004 9616028 2030-11-12 Drug product 2019-05-24 N210874-004 9616028*PED 2031-05-12 Pediatric extension
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 5 · 180 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N210874-001 QTERNMET XR 2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-002 QTERNMET XR 5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-003 QTERNMET XR 5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-004 QTERNMET XR 10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N210874-001 QTERNMET XR 2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 c2088c7a36db…2026-10-15 13:18:30 2026-09 N210874-002 QTERNMET XR 5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 c2088c7a36db…2026-10-15 13:18:30 2026-09 N210874-003 QTERNMET XR 5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 c2088c7a36db…2026-10-15 13:18:30 2026-09 N210874-004 QTERNMET XR 10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 c2088c7a36db…2026-09-14 22:38:34 2026-08 N210874-001 QTERNMET XR 2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N210874-002 QTERNMET XR 5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N210874-003 QTERNMET XR 5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N210874-004 QTERNMET XR 10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 84e616aacf4f…2026-08-18 06:07:40 2026-07 N210874-001 QTERNMET XR 2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N210874-002 QTERNMET XR 5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N210874-003 QTERNMET XR 5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N210874-004 QTERNMET XR 10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N210874-001 QTERNMET XR 2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N210874-002 QTERNMET XR 5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N210874-003 QTERNMET XR 5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N210874-004 QTERNMET XR 10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N210874-001 QTERNMET XR 2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N210874-002 QTERNMET XR 5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N210874-003 QTERNMET XR 5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N210874-004 QTERNMET XR 10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N210874-001 QTERNMET XR 2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N210874-002 QTERNMET XR 5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N210874-003 QTERNMET XR 5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N210874-004 QTERNMET XR 10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N210874-001 QTERNMET XR 2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N210874-002 QTERNMET XR 5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N210874-003 QTERNMET XR 5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N210874-004 QTERNMET XR 10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N210874-001 QTERNMET XR 2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N210874-002 QTERNMET XR 5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N210874-003 QTERNMET XR 5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 b8a1b40f171c…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N210874-004 QTERNMET XR 10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N210874-001 QTERNMET XR 2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N210874-002 QTERNMET XR 5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N210874-003 QTERNMET XR 5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 03ed91905a0d…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N210874-004 QTERNMET XR 10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE / ORAL RLD 2019-05-02 03ed91905a0d…
Observed Orange Book patent history# Patent history page 1 of 37 · 1,464 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N210874-001 6515117 2025-10-04 U-493 Drug substance, Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-001 6515117*PED 2026-04-04 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-001 8501698 2027-06-20 U-493 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-001 8501698*PED 2027-12-20 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-001 8716251 2028-03-21 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-001 8716251*PED 2028-09-21 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-001 7919598 2029-12-16 Drug substance 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-001 7919598*PED 2030-06-16 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-001 9616028 2030-11-12 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-001 9616028*PED 2031-05-12 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-002 6515117 2025-10-04 U-493 Drug substance, Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-002 6515117*PED 2026-04-04 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-002 8501698 2027-06-20 U-493 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-002 8501698*PED 2027-12-20 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-002 8716251 2028-03-21 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-002 8716251*PED 2028-09-21 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-002 7919598 2029-12-16 Drug substance 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-002 7919598*PED 2030-06-16 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-002 9616028 2030-11-12 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-002 9616028*PED 2031-05-12 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-003 6515117 2025-10-04 U-493 Drug substance, Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-003 6515117*PED 2026-04-04 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-003 8501698 2027-06-20 U-493 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-003 8501698*PED 2027-12-20 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-003 8716251 2028-03-21 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-003 8716251*PED 2028-09-21 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-003 7919598 2029-12-16 Drug substance 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-003 7919598*PED 2030-06-16 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-003 9616028 2030-11-12 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-003 9616028*PED 2031-05-12 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-004 6515117 2025-10-04 U-493 Drug substance, Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-004 6515117*PED 2026-04-04 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-004 8501698 2027-06-20 U-493 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-004 8501698*PED 2027-12-20 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-004 8716251 2028-03-21 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-004 8716251*PED 2028-09-21 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-004 7919598 2029-12-16 Drug substance 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-004 7919598*PED 2030-06-16 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-004 9616028 2030-11-12 Drug product 2019-05-24 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N210874-004 9616028*PED 2031-05-12 Pediatric extension d4dbc9d85df4…
Observed Orange Book exclusivity history# Exclusivity history page 1 of 2 · 68 observed states.
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Marketing start Marketing end Sample Exclude flag Status 0310-6925-60 00310692560 60 TABLET, FILM COATED in 1 BOTTLE (0310-6925-60) 2020-06-01 0000-00-00 No No Current